An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
Top results in this bookTable of Contents
Urinary Incontinence in Neurological Disease: Management of Lower Urinary Tract Dysfunction in Neurological Disease.
National Clinical Guideline Centre (UK).
London: Royal College of Physicians (UK); 2012 Aug. (NICE Clinical Guidelines, No. 148.)
Spinal Injury: Assessment and Initial Management.
London: National Institute for Health and Care Excellence (NICE); 2016 Feb. (NICE Guideline, No. 41.)
Suspected neurological conditions: recognition and referral.
National Guideline Centre (UK).
London: National Institute for Health and Care Excellence (NICE); 2019 May. (NICE Guideline, No. 127.)
The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research.
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda.
Washington (DC): National Academies Press (US); 2017 Jan 12.
Cerebral palsy in under 25s: assessment and management.
National Guideline Alliance (UK).
London: National Institute for Health and Care Excellence (NICE); 2017 Jan. (NICE Guideline, No. 62.)
Neuropathic pain in adults: pharmacological management in non-specialist settings.
London: National Institute for Health and Care Excellence (NICE); 2020 Sep 22. (NICE Clinical Guidelines, No. 173.)
Spinal metastases and metastatic spinal cord compression.
London: National Institute for Health and Care Excellence (NICE); 2023 Sep 6. (NICE Clinical Guidelines, No. 234.)
Faecal Incontinence: The Management of Faecal Incontinence in Adults.
London: National Collaborating Centre for Acute Care (UK); 2007. (NICE Clinical Guidelines, No. 49.)
WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents.
Geneva: World Health Organization; 2018.
WHO Guidelines on Physical Activity and Sedentary Behaviour.
Geneva: World Health Organization; 2020.
Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto): CADTH Reimbursement Review: Therapeutic area: Metastatic castration-resistant prostate cancer [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 May.
Care of Dying Adults in the Last Days of Life.
London: National Institute for Health and Care Excellence (NICE); 2015 Dec 16. (NICE Guideline, No. 31.)
Major Trauma: Assessment and Initial Management.
London: National Institute for Health and Care Excellence (NICE); 2016 Feb. (NICE Guideline, No. 39.)
World Report on Disability 2011.
Geneva: World Health Organization; 2011.
Therapeutic Use of Medical Cannabis in New York State [Internet].
Slawek D, Arnsten JH, Whitley SD, et al.
Baltimore (MD): Johns Hopkins University; 2022 Jan.
COVID-19 rapid guideline: delivery of radiotherapy.
London: National Institute for Health and Care Excellence (NICE); 2021 Feb 12. (NICE Guideline, No. 162.)
Suspected sepsis: recognition, diagnosis and early management.
London: National Institute for Health and Care Excellence (NICE); 2024 Jan 31. (NICE Guideline, No. 51.)
Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto): CADTH Reimbursement Recommendation: Indication: Treatment of adults with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have received at least one androgen receptor pathway inhibitor and taxane-based chemotherapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Mar.
Trastuzumab Deruxtecan (Enhertu): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior treatment with an anti-HER2-based regimen in the metastatic setting or developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Oct.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on